Thursday, 8 October 2026European Markets

Euro Gains 14% Against Dollar as US Currency Hits Lowest Level Since 2022

The euro has climbed 14% against the US dollar in 2025, while the British pound gained 7%, as the greenback fell to its lowest level since 2022. The currency realignment occurs amid upcoming Fed leadership changes and geopolitical shifts including US-Iran nuclear deal progress.

Euro Gains 14% Against Dollar as US Currency Hits Lowest Level Since 2022
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro reached a 14% gain against the US dollar in 2025, marking the dollar's weakest performance since 2022 against major currencies. The British pound advanced 7% over the same period.

Currency markets are experiencing heightened volatility ahead of a Fed leadership transition in June 2026, when a new chair will replace Jerome Powell. The dollar weakness comes as the Federal Reserve navigates this institutional change.

Progress on US-Iran nuclear deal negotiations is contributing to geopolitical shifts affecting currency positions. The Swiss franc has attracted safe-haven demand during the turbulence.

Emerging markets face pressure from the currency realignment. The Turkish lira dropped 17% following a carry trade collapse, highlighting stress in developing economies exposed to dollar movements.

Jordan Rochester, analyst at Mizuho Bank, forecasts the British pound could fall below $1.30 despite recent gains. Simon Phillips, managing director at No1 Currency, noted continued pressure on GBP positions.

The euro's strength benefits European exporters facing dollar-denominated commodity costs while potentially dampening export competitiveness. European Central Bank officials have not yet signaled concerns about the currency's appreciation.

Currency analysts assign 85% confidence to forecasts of continued dollar pressure. The trend represents a reversal from the dollar's post-pandemic strength that dominated forex markets through 2022.

European equity markets have advanced alongside currency gains, with the Stoxx 600 reaching a record 583.4 points. The FTSE 100 closed at 9,911, approaching the psychologically significant 10,000 level.

Gold prices climbed above $4,100 per ounce as dollar weakness boosted demand for alternative assets. European investors holding dollar-denominated assets face currency headwinds on returns.

The currency shift affects transatlantic trade flows and corporate earnings for European multinationals with US operations. Companies report quarterly results with euro-dollar exchange rates as a key variable in guidance.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com